ASCLETIS-B (01672) Proposes Placement of 69.256 Million Shares at Approximately 4% Discount, Targeting Net Proceeds of About HK$835.3 Million

Stock News02-03

ASCLETIS-B (01672) announced that on February 3, 2026, the company proposes to place 69.256 million shares, representing approximately 6.98% of the company's issued share capital as of the date of this announcement (which is 992 million shares, excluding 7.0842 million treasury shares).

The placing price is set at HK$12.18 per share, representing a discount of approximately 4.0% to the closing price of HK$12.69 per share on February 2.

The gross proceeds from the placing are expected to amount to approximately HK$843.5 million, while the net proceeds are anticipated to be approximately HK$835.3 million.

Approximately 90% of the net proceeds from the placing are intended to be used for the preparation, foundational work, and initiation of the global Phase III clinical trial for ASC30, an oral small-molecule GLP-1 receptor agonist for the treatment of obesity.

Approximately 10% of the net proceeds from the placing are proposed to be used as working capital and for other general corporate purposes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment